Homepage of the Project: www.digimed-bayern.de
P4 medicine (predictive, preventive, personalized, participatory) is one of the world's most promising developments for improved, holistic and efficient health care. DigiMed Bayern's goal is to guide Bavaria into this medicine of the future with a flagship project.
The flagship P4-medicine project DigiMed Bayern was launched at the end of 2018 with over 20 million € funding by the Bavarian State Ministry of Health and Care. DigiMed Bayern combines comprehensive datasets of patients diagnosed with atherosclerotic diseases, such as coronary heart disease and stroke, or with genetic risk factors. This dataset will be further enriched with state-of-the-art multi-dimensional molecular characterization (-omics technologies) of associated sample material. For the integrative analysis of the resulting "Big Data", an ethically and legally compliant, highly secure and sustainable IT infrastructure will be fundamentally designed and implemented. Finally, patients and persons at risk will benefit from advancements in disease risk prediction, targeted prevention, diagnosis and treatment.
Superior goals of DigiMed Bayern
1. Using the example of atherosclerosis, a first analysis of comprehensive data sets in the sense of digital medicine of the future is carried out. All those involved in the health care system in Bavaria should benefit directly: the prediction for coronary heart disease (CHD) and stroke should be made more accurate in the short term and preventive treatment should be improved. In the medium to long term improvements in diagnosis and therapy are pursued. The population-wide identification of familial hypercholesterinemia as an exemplary risk factor for atherosclerosis should be sustainably improved.
2. The technical, legal and social possibilities and limitations of P4 medicine are recorded, promoted and documented by means of concrete implementation. This includes a proactive multi-directional information exchange with all those involved in health, with a focus on systemic development.
3. Resulting insights and structures should be expandable in the health system, in research and in the economy and be transferable to other diseases. In particular, an exemplary and transferable integrated digital infrastructure should be created.
4. Bavaria as a location for P4 medicine should be substantially developed, including international perception and internationally networking.
Planned duration:
Q4 2018 to Q4 2023
Scientific Directorate:
German Heart Centre Munich
Managing Directorate:
BioM Biotech Cluster Development GmbH
Initially involved Institutions
More information:
Homepage of the Project: www.digimed-bayern.de
Digital Health, Managing Director DigiMed Bayern
